Related Experiment Video
Updated: Jun 19, 2026
In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
Published on: August 12, 2017
Challenges in treating primary immune thrombocytopenia patients undergoing COVID-19 vaccination: A retrospective
Huiping Xu1, Beibei Zhang2, Linjun Xie2,3
1Department of Clinical Nutrition, The First Hospital of Putian City, Putian 351100, Fujian, P.R. China.
Insights
COVID-19 vaccination may impact primary immune thrombocytopenia (ITP) treatment. Vaccinated ITP patients showed a lower short-term response to initial therapy compared to unvaccinated patients.
Area of Science:
- Hematology
- Immunology
- Vaccinology
Background:
- The COVID-19 pandemic necessitated widespread vaccination efforts.
- Primary immune thrombocytopenia (ITP) management has presented new challenges post-COVID-19 vaccination.
Purpose of the Study:
- To compare the treatment response in de novo ITP patients who received COVID-19 vaccination versus those who did not.
- To evaluate the efficacy of initial ITP treatment strategies in vaccinated versus unvaccinated cohorts.
Main Methods:
- A comparative study involving 25 de novo ITP patients post-COVID-19 vaccination (Group 1) and 25 pre-pandemic controls (Group 2).
- Statistical analysis included Mann-Whitney U test and Fisher's exact test to compare treatment outcomes.
- Platelet counts and need for combination therapy were key outcome measures.
Main Results:
- Group 1 (vaccinated) exhibited significantly lower median platelet counts on Day 3 and Day 7 compared to Group 2 (unvaccinated).
- Patients in Group 1 demonstrated a suboptimal short-term response to glucocorticoid monotherapy.
- A higher proportion of vaccinated patients required second-line or combination therapies (IVIG, TPO-RAs, rituximab).
Conclusions:
- COVID-19 vaccination may be associated with a reduced response rate to first-line treatment in de novo ITP patients.
- Findings suggest potential implications for ITP management strategies in vaccinated individuals.
- Further research is warranted to confirm these observations and elucidate underlying mechanisms.
Background:
Since the outbreak of COVID-19 in December 2019, countries around the world, including China, have been administering COVID-19 vaccines in response to the pandemic. Our center has observed that treating patients with primary immune thrombocytopenia (ITP) has become more challenging in this context.
Methods:
This study compared the treatment response of 25 de novo ITP patients who had received a COVID-19 vaccination (Group 1) with an equal number of de novo ITP patients randomly selected from the 2 years prior to the COVID-19 pandemic (Group 2) by using the Mann-Whitney U test and Fisher's exact.
Results:
Patients in both groups had predominantly female gender with similar age and baseline platelet counts. However, on Day 3, the median platelets were 22 and 49 × 109/L, and on Day 7, they were 74 and 159 × 109/L, respectively (P < 0.05). Compared to Group 2, Group 1 showed a suboptimal short-term response to glucocorticoid monotherapy, with a higher proportion of patients requiring combination therapy with other drugs including intravenous immunoglobulin, thrombopoietin receptor agonists, and rituximab. After subgroup analysis, a significant difference was observed in the proportion of patients requiring second-line therapy between the two groups.
Conclusions:
Our study suggests that COVID-19 vaccination may lead to a lower response rate to first-line treatment in de novo ITP patients. Nevertheless, it is crucial to acknowledge the inherent limitations in this conclusion. Further studies are needed to confirm these findings and investigate the underlying mechanisms.
Related Concept Videos
02:45Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
01:18Endocarditis III: Medical Management
01:14Myocarditis III: Medical Management
01:29Venous Thrombosis III: Interprofessional Care